# Effects of acupuncture and moxibustion therapy on endometrial receptivity of infertile women with in vitro fertilization–embryo transfer: status quo and countermeasures

**Authors:** Xiao-Zhu Guo, Zhen Qin, Deng-Hui Wu, Han Han, Yan-Hua Han, Xiao-Ke Wu, Yue-Hui Zhang

PMC · DOI: 10.3389/fmed.2025.1702214 · Frontiers in Medicine · 2026-02-10

## TL;DR

This paper reviews how acupuncture and moxibustion may improve endometrial receptivity in IVF patients, highlighting current evidence and future research needs.

## Contribution

A systematic review of acupuncture and moxibustion subtypes and their mechanisms in improving endometrial receptivity for IVF-ET.

## Key findings

- Acupuncture and moxibustion improve endometrial receptivity by regulating thickness, blood flow, hormones, and molecular pathways.
- Combined therapies like warm needling and acupuncture enhance efficacy further.
- High-quality RCTs are needed to confirm and standardize these interventions.

## Abstract

In vitro fertilization–embryo transfer (IVF-ET) is a core assisted reproductive technology (ART) for infertile couples, but poor endometrial receptivity (ER) severely impairs embryo implantation and reduces success rates, imposing significant psychological and economic burdens. Acupuncture and moxibustion have been validated to improve ER via multiple mechanisms, yet no reviews systematically summarize clinical evidence on their subtypes and underlying pathways to guide future research.

This study aims to comprehensively synthesize recent advances in acupuncture and moxibustion for enhancing ER in IVF-ET patients, promoting clinical application and research awareness.

A systematic literature search was conducted across PubMed, Web of Science, CNKI, and WanFang databases (January 2020–June 2025), supplemented with seminal studies. After screening, 214 studies were included for qualitative synthesis; methodological quality was assessed using RoB 2.0 (RCTs) and NOS (non-RCTs).

Acupuncture (traditional manual, electroacupuncture, and TEAS) and moxibustion (wheat, herbal cake, and warm uterus moxibustion) improve ER by regulating endometrial thickness, blood flow (e.g., reduced PI/RI), hormone levels (E2 and P), and type A endometrium ratio. Combined therapies (e.g., warm needling + acupuncture) further enhance efficacy. Mechanisms involve modulating autophagy (AMPK/mTOR pathway), pinopode-related molecules (LIF, integrin αvβ3), non-coding RNAs (miR-449a, circRNAs), and VEGF-mediated angiogenesis.

Acupuncture and moxibustion are promising adjunctive therapies for ER enhancement in IVF-ET, but high-quality, standardized RCTs are needed to confirm efficacy, standardize protocols, and reduce bias.

## Linked entities

- **Proteins:** LIF (LIF interleukin 6 family cytokine), VEGFA (vascular endothelial growth factor A)

## Full-text entities

- **Genes:** Lif (LIF, interleukin 6 family cytokine) [NCBI Gene 60584], LAMP2 (lysosome associated membrane protein 2) [NCBI Gene 3920] {aka CD107b, DND, LAMP-2, LAMPB, LGP-96, LGP110}, SPP1 (secreted phosphoprotein 1) [NCBI Gene 6696] {aka BNSP, BSPI, ETA-1, OPN}, HBEGF (heparin binding EGF like growth factor) [NCBI Gene 1839] {aka DTR, DTS, DTSF, HEGFL}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, LIF (LIF interleukin 6 family cytokine) [NCBI Gene 3976] {aka CDF, DIA, HILDA, MLPLI}, ITGB3 (integrin subunit beta 3) [NCBI Gene 3690] {aka BDPLT16, BDPLT2, BDPLT24, CD61, FMAIT1, GP3A}, PGF (placental growth factor) [NCBI Gene 5228] {aka D12S1900, PGFL, PIGF, PLGF, PlGF-2, SHGC-10760}, Pik3cb (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta) [NCBI Gene 85243], MIR449A (microRNA 449a) [NCBI Gene 554213] {aka MIRN449, MIRN449A, hsa-mir-449, mir-449a}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, KDR (kinase insert domain receptor) [NCBI Gene 3791] {aka CD309, FLK1, VEGFR, VEGFR2}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, TP53INP2 (tumor protein p53 inducible nuclear protein 2) [NCBI Gene 58476] {aka C20orf110, DOR, PINH, dJ1181N3.1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, MIR135B (microRNA 135b) [NCBI Gene 442891] {aka MIRN135B, mir-135b}, IL6ST (interleukin 6 cytokine family signal transducer) [NCBI Gene 3572] {aka CD130, CDW130, GP130, HIES4, HIES4A, HIES4B}, LIPN (lipase family member N) [NCBI Gene 643418] {aka ARCI8, LI4, LIPL4, bA186O14.3}, MIR543 (microRNA 543) [NCBI Gene 100126335] {aka MIRN543, hsa-mir-543, mir-543}, VEGFB (vascular endothelial growth factor B) [NCBI Gene 7423] {aka VEGFL, VRF}, NEAT1 (nuclear paraspeckle assembly transcript 1) [NCBI Gene 283131] {aka LINC00084, NCRNA00084, TP53LC15, TncRNA, VINC}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, NUP62 (nucleoporin 62) [NCBI Gene 23636] {aka IBSN, SNDI, p62}, GNRH1 (gonadotropin releasing hormone 1) [NCBI Gene 2796] {aka GNRH, GRH, LHRH, LNRH}, PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562] {aka AMPK, AMPK alpha 1, AMPKa1}, CLDN1 (claudin 1) [NCBI Gene 9076] {aka CLD1, ILVASC, SEMP1}, JAK1 (Janus kinase 1) [NCBI Gene 3716] {aka AIIDE, JAK1A, JAK1B, JTK3}, AMH (anti-Mullerian hormone) [NCBI Gene 268] {aka MIF, MIS}, MIR3135B (microRNA 3135b) [NCBI Gene 100616218], Vegfa (vascular endothelial growth factor A) [NCBI Gene 83785] {aka VEGF-A, VEGF111, VEGF164, VPF, Vegf}, VEGFC (vascular endothelial growth factor C) [NCBI Gene 7424] {aka Flt4-L, LMPH1D, LMPHM4, VRP}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, Akt1 (AKT serine/threonine kinase 1) [NCBI Gene 24185] {aka Akt}, ITGAV (integrin subunit alpha V) [NCBI Gene 3685] {aka CD51, IDNDC, MSK8, VNRA, VTNR}, TCL1A (TCL1 family AKT coactivator A) [NCBI Gene 8115] {aka TCL1}, OXT (oxytocin/neurophysin I prepropeptide) [NCBI Gene 5020] {aka OT, OT-NPI, OXT-NPI}, TNFRSF8 (TNF receptor superfamily member 8) [NCBI Gene 943] {aka CD30, D1S166E, Ki-1}, SP9 (Sp9 transcription factor) [NCBI Gene 100131390] {aka ZNF990}, TUNAR (transmembrane neural differentiation associated intracellular calcium regulator) [NCBI Gene 100507043] {aka BNLN, HI-LNC78, LINC00617, TUNA, pTUNAR}, IGKV4-1 (immunoglobulin kappa variable 4-1) [NCBI Gene 28908] {aka B3, IGKV41}, PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 5295] {aka AGM7, GRB1, IMD36, p85, p85-ALPHA, p85alpha}, CTCF (CCCTC-binding factor) [NCBI Gene 10664] {aka CFAP108, FAP108, MRD21}, NOS3 (nitric oxide synthase 3) [NCBI Gene 4846] {aka EC-NOS, ECNOS, MYMY8, NOSIII, cNOS, eNOS}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, HOXA10 [NCBI Gene 103692129], HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, Kdr (kinase insert domain receptor) [NCBI Gene 25589] {aka Vegfr-2}, Vim (vimentin) [NCBI Gene 81818], PRKAA2 (protein kinase AMP-activated catalytic subunit alpha 2) [NCBI Gene 5563] {aka AMPK, AMPK2, AMPKa2, PRKAA}, Nos3 (nitric oxide synthase 3) [NCBI Gene 24600] {aka eNos}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, HOXA10 (homeobox A10) [NCBI Gene 3206] {aka HOX1, HOX1.8, HOX1H, PL}
- **Diseases:** anxiety (MESH:D001007), FET (MESH:D002062), pre-eclampsia (MESH:D011225), abdominal pain (MESH:D015746), tumor (MESH:D009369), RIF (MESH:D051437), IVF (MESH:C537182), angiogenesis (MESH:D016510), female infertility (MESH:D007247), follicular growth disorders (MESH:D006130), EMs (MESH:D004715), fallopian tube diseases (MESH:D005184), pain (MESH:D010146), POF (MESH:D016649), ET (MESH:D016751), inflammation (MESH:D007249), pruritus (MESH:D011537), kidney deficiency (MESH:D007680), dermatitis (MESH:D003872), nausea (MESH:D009325), bleeding (MESH:D006470), OHSS (MESH:D016471), dizziness (MESH:D004244), ADRs (MESH:D064420), RM (MESH:D000026), Infertility (MESH:D007246), preterm delivery (MESH:D047928), hypertensive disorders of pregnancy (MESH:D046110), PCOS (MESH:D011085), breast tenderness (MESH:D061325), IVF-ET (MESH:D020964), IVF (MESH:C566179), diminished ovarian reserve (MESH:D010049), ovulatory dysfunction (MESH:D006331), miscarriage (MESH:D000022), depressed (MESH:D003866), bruising (MESH:D003288), ER (MESH:D014591), nausea, vomiting (MESH:D020250)
- **Chemicals:** CC (MESH:D002996), cortisol (MESH:D006854), E2 (MESH:D004958), P (MESH:D010758), T (MESH:D014316), NO (MESH:D009569), progesterone (MESH:D011374), testosterone (MESH:D013739), LE (MESH:D000077289), CHM (-), steroid (MESH:D013256)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Cell lines:** GB26 — Epinephelus awoara (Yellow grouper), Spontaneously immortalized cell line (CVCL_S928), BL17 — Homo sapiens (Human), Bladder carcinoma, Cancer cell line (CVCL_M007), BL21 — Homo sapiens (Human), EBV-related Burkitt lymphoma, Cancer cell line (CVCL_M639), BL15 — Homo sapiens (Human), Transformed cell line (CVCL_L062)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12929554/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12929554/full.md

## References

214 references — full list in the complete paper: https://tomesphere.com/paper/PMC12929554/full.md

---
Source: https://tomesphere.com/paper/PMC12929554